AR079842A1 - Derivados de pirrolopiridina benzoico, composicion farmaceutica que los comprende y su utilizacion en la fabricacion de un medicamento para el tratamiento de las enfermedades neurodegenerativas - Google Patents
Derivados de pirrolopiridina benzoico, composicion farmaceutica que los comprende y su utilizacion en la fabricacion de un medicamento para el tratamiento de las enfermedades neurodegenerativasInfo
- Publication number
- AR079842A1 AR079842A1 ARP110100029A ARP110100029A AR079842A1 AR 079842 A1 AR079842 A1 AR 079842A1 AR P110100029 A ARP110100029 A AR P110100029A AR P110100029 A ARP110100029 A AR P110100029A AR 079842 A1 AR079842 A1 AR 079842A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl group
- hydrogen atom
- phenylsulfonyl
- pyrrolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Estos compuestos son moduladores de los receptores nucleares NURR-1. Reivindicacion 1: Compuesto de formula (1) en la cual: uno de los grupos A representa un átomo de nitrogeno y los otros grupos A representan un átomo de carbono; Cy representa un fenilo o un nucleo heteroaromático de 5 o 6 eslabones; R1 representa un átomo de hidrogeno, halogeno, un grupo alquilo C1-4, eventualmente, total o parcialmente halogenado, o un grupo alcoxi C1-4; R2 y R3 representan, cada uno, independientemente del otro, un átomo de hidrogeno, halogeno, un grupo alquilo C1-4, hidroxi, o un grupo alcoxi C1-4; R4 y R5 representan, cada uno, independientemente del otro, un átomo de hidrogeno, halogeno, un grupo alquilo C1-4 o un grupo hidroxi; o R4 y R5 forman junto con el átomo de carbono al que están unidos un grupo etileno (C=CH2) o un grupo carbonilo (C=O); R6 representa un grupo -COOR9 o un grupo -SO2NHR10, -CONHNHCOOR11, -CONR12R13 o -CONHSO2R14, o un grupo de las formulas (2); R7 representa un fenilo, eventualmente sustituido por un grupo alquilo C1-4, o un nucleo heteroaromático que tiene de 6 a 10 eslabones, eventualmente, sustituido por un grupo alquilo C1-4; R8 representa un átomo de hidrogeno, un grupo alquilo C1-4 o un átomo de halogeno; R9 representa un átomo de hidrogeno o un grupo alquilo C1-4; R10, R11, R12, R13 y R14 representan, cada uno, independientemente del otro, un átomo de hidrogeno o un grupo alquilo C1-4; o una sal farmacéuticamente aceptable de dicho compuesto de formula (1); a excepcion de los compuestos siguientes: ácido 2-(1-fenilsulfonil-1H-pirrolo[2,3-b]piridin-2-il-carbonil)-benzoico; N,N-dietil-4-[hidroxi-[1-(fenilsulfonil)-1H-pirrolo[2,3-b]piridin-2-il]metil]-2-metoxi-3-piridincarboxamida; N,N-dietil-2-metoxi-4-[[1-(fenilsulfonil)-1H-pirrolo[2,3-b]piridin-2-il]carbonil]-3- piridincarboxamida; N,N-dietil-4-[1-hidroxi-1-[1-(fenilsulfonil)-1H-pirrolo[2,3-b]piridin-2-il]etil]-2-metoxi-3-piridincarboxamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1050113A FR2955110A1 (fr) | 2010-01-08 | 2010-01-08 | Nouveaux derives de type pyrrolopyridine benzoique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079842A1 true AR079842A1 (es) | 2012-02-22 |
Family
ID=42124595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100029A AR079842A1 (es) | 2010-01-08 | 2011-01-06 | Derivados de pirrolopiridina benzoico, composicion farmaceutica que los comprende y su utilizacion en la fabricacion de un medicamento para el tratamiento de las enfermedades neurodegenerativas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8546385B2 (es) |
| EP (1) | EP2521727B1 (es) |
| JP (1) | JP2013516448A (es) |
| KR (1) | KR20120123042A (es) |
| CN (1) | CN102753552A (es) |
| AR (1) | AR079842A1 (es) |
| AU (1) | AU2011204518A1 (es) |
| BR (1) | BR112012016844A2 (es) |
| CA (1) | CA2785876A1 (es) |
| DK (1) | DK2521727T3 (es) |
| EA (1) | EA201290601A1 (es) |
| ES (1) | ES2478191T3 (es) |
| FR (1) | FR2955110A1 (es) |
| HK (1) | HK1178893A1 (es) |
| MX (1) | MX2012007968A (es) |
| PL (1) | PL2521727T3 (es) |
| PT (1) | PT2521727E (es) |
| SA (1) | SA111320080B1 (es) |
| TW (1) | TWI473806B (es) |
| UY (1) | UY33166A (es) |
| WO (1) | WO2011083278A1 (es) |
| ZA (1) | ZA201204863B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102347368B1 (ko) | 2020-11-03 | 2022-01-07 | (주)케이메디켐 | 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA002817B1 (ru) | 1996-12-13 | 2002-10-31 | Авентис Фармасьютикалз Продактс Инк. | Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)азагетероциклиламида |
| ATE482945T1 (de) * | 1998-05-26 | 2010-10-15 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
| GB0119911D0 (en) | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| KR20130023381A (ko) | 2003-07-17 | 2013-03-07 | 플렉시콘, 인코퍼레이티드 | Ｐｐａｒ 활성 화합물 |
| US8455489B2 (en) | 2003-11-10 | 2013-06-04 | Exelixis, Inc. | Substituted pyrimidine compositions and methods of use |
| FR2890072A1 (fr) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
| FR2903105A1 (fr) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
| FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2903106B1 (fr) | 2006-07-03 | 2010-07-30 | Sanofi Aventis | Utilisations de 2-benzoyl-imidazopyridines en therapeutique |
| US20080200471A1 (en) | 2007-02-16 | 2008-08-21 | Memory Pharmaceuticals Corporation | 6' substituted compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
-
2010
- 2010-01-08 FR FR1050113A patent/FR2955110A1/fr not_active Withdrawn
-
2011
- 2011-01-05 SA SA111320080A patent/SA111320080B1/ar unknown
- 2011-01-06 AR ARP110100029A patent/AR079842A1/es unknown
- 2011-01-07 KR KR1020127017543A patent/KR20120123042A/ko not_active Application Discontinuation
- 2011-01-07 UY UY0001033166A patent/UY33166A/es not_active Application Discontinuation
- 2011-01-07 TW TW100100707A patent/TWI473806B/zh not_active IP Right Cessation
- 2011-01-07 ES ES11704261.4T patent/ES2478191T3/es active Active
- 2011-01-07 JP JP2012547533A patent/JP2013516448A/ja active Pending
- 2011-01-07 PT PT117042614T patent/PT2521727E/pt unknown
- 2011-01-07 DK DK11704261.4T patent/DK2521727T3/da active
- 2011-01-07 WO PCT/FR2011/050023 patent/WO2011083278A1/fr active Application Filing
- 2011-01-07 CA CA2785876A patent/CA2785876A1/fr not_active Abandoned
- 2011-01-07 CN CN2011800094959A patent/CN102753552A/zh active Pending
- 2011-01-07 AU AU2011204518A patent/AU2011204518A1/en not_active Abandoned
- 2011-01-07 EA EA201290601A patent/EA201290601A1/ru unknown
- 2011-01-07 US US13/519,774 patent/US8546385B2/en not_active Expired - Fee Related
- 2011-01-07 BR BR112012016844-4A patent/BR112012016844A2/pt not_active IP Right Cessation
- 2011-01-07 MX MX2012007968A patent/MX2012007968A/es not_active Application Discontinuation
- 2011-01-07 PL PL11704261T patent/PL2521727T3/pl unknown
- 2011-01-07 EP EP11704261.4A patent/EP2521727B1/fr active Active
-
2012
- 2012-06-29 ZA ZA2012/04863A patent/ZA201204863B/en unknown
-
2013
- 2013-05-14 HK HK13105757.7A patent/HK1178893A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SA111320080B1 (ar) | 2014-06-23 |
| WO2011083278A1 (fr) | 2011-07-14 |
| AU2011204518A1 (en) | 2012-07-26 |
| HK1178893A1 (en) | 2013-09-19 |
| TWI473806B (zh) | 2015-02-21 |
| CN102753552A (zh) | 2012-10-24 |
| CA2785876A1 (fr) | 2011-07-14 |
| TW201144307A (en) | 2011-12-16 |
| PT2521727E (pt) | 2014-06-25 |
| UY33166A (es) | 2011-08-31 |
| US20120302560A1 (en) | 2012-11-29 |
| KR20120123042A (ko) | 2012-11-07 |
| ZA201204863B (en) | 2013-09-25 |
| ES2478191T3 (es) | 2014-07-18 |
| EP2521727A1 (fr) | 2012-11-14 |
| DK2521727T3 (da) | 2014-06-16 |
| PL2521727T3 (pl) | 2014-08-29 |
| EP2521727B1 (fr) | 2014-03-19 |
| BR112012016844A2 (pt) | 2018-05-08 |
| EA201290601A1 (ru) | 2012-12-28 |
| US8546385B2 (en) | 2013-10-01 |
| MX2012007968A (es) | 2012-08-03 |
| JP2013516448A (ja) | 2013-05-13 |
| FR2955110A1 (fr) | 2011-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR097079A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR088235A1 (es) | Derivados de pirazoloquinolina | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR090587A1 (es) | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR085750A1 (es) | Derivados de pirazolo-pirimidina | |
| AR095570A1 (es) | Derivados de urea | |
| AR075614A1 (es) | Piperidinas 1, 4-disustituidas, una composicion farmaceutica que las comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por los receptores v1a de vasopresina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |